U.S. markets open in 7 hours 45 minutes

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
2.4400-0.1100 (-4.31%)
Al cierre: 04:00PM EDT
2.4000 -0.04 (-1.64%)
Fuera de horario: 07:56PM EDT

ChromaDex Corporation

10900 Wilshire Blvd
Suite 600
Los Angeles, CA 90024
United States
310 388 6706
https://www.chromadex.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo106

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Frank Louis Jaksch Jr.Co-Founder & Chairman70kN/D1968
Mr. Robert N. FriedCEO & Director768.96kN/D1960
Ms. Brianna GerberChief Financial Officer482.15kN/D1981
Dr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific AffairsN/DN/DN/D
Alex WorshamVice President of Global Marketing & CommunicationsN/DN/DN/D
Mr. David KroesSenior Vice President of People MattersN/DN/DN/D
Ms. Chu YanManaging Director of Asia PacificN/DN/DN/D
Mr. Jason CampbellSenior Vice President of Business DevelopmentN/DN/DN/D
Kendall KnyschHead of Media Relations & PartnershipsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Gestión corporativa

La calificación ISS Governance QuickScore de ChromaDex Corporation a partir del 1 de junio de 2024 es 4. Las puntuaciones principales son Auditoría: 5; Junta: 5; Derechos del accionista: 3; Compensación: 6.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.